Stephen J Freedland, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka, Ronald F Tutrone, Balaji Venugopal, Henry H Woo, Miguel Ramirez-Backhaus, Jamal Tarazi, Yiyun Tang, Arijit Ganguli, Gabriel P Haas, Neal D Shore
{"title":"通俗易懂的摘要:恩扎鲁胺联合或不联合利血平治疗能否改善高危生化复发患者的预后并影响其生活质量?","authors":"Stephen J Freedland, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka, Ronald F Tutrone, Balaji Venugopal, Henry H Woo, Miguel Ramirez-Backhaus, Jamal Tarazi, Yiyun Tang, Arijit Ganguli, Gabriel P Haas, Neal D Shore","doi":"10.1080/14796694.2024.2426425","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-14"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?\",\"authors\":\"Stephen J Freedland, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka, Ronald F Tutrone, Balaji Venugopal, Henry H Woo, Miguel Ramirez-Backhaus, Jamal Tarazi, Yiyun Tang, Arijit Ganguli, Gabriel P Haas, Neal D Shore\",\"doi\":\"10.1080/14796694.2024.2426425\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"1-14\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-12-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2024.2426425\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2426425","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
期刊介绍:
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.